Status:
UNKNOWN
Doxycycline Treatment in Mild Thyroid-Associated Ophthalmopathy
Lead Sponsor:
Sun Yat-sen University
Conditions:
Graves Ophthalmopathy
Graves Disease
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
The aim of this study is to evaluate the effects of subantimicrobial dose doxycycline (50 mg/d), administered for 12 weeks, on patients with mild Thyroid-Associated Ophthalmopathy (TAO).
Detailed Description
Thyroid-Associated Ophthalmopathy is an autoimmune disease that can be treated by corticosteroids and surgery. But they often cause severe side-effects and are usually used for treating moderate-sever...
Eligibility Criteria
Inclusion
- Clinical diagnosis of Thyroid-associated ophthalmopathy
- Mild TAO
- Normal serum free thyroxine and free triiodothyronine concentrations
- No previous specific therapy for TAO, except for local measures
- Written informed consent is obtained
Exclusion
- Pregnant females as determined by positive (serum or urine) hCG test at screening or prior to dosing, or lactating females
- Uncontrolled diabetes or hypertension
- History of mental / psychiatric disorder
- Hepatic dysfunction (Alb, AST, ALT and Alkaline phosphates levels must be within normal range for eligibility)
- Renal impairment (Urea and Creatinine levels must be within normal range)
- Tetracycline allergy or intolerance
Key Trial Info
Start Date :
July 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT02203682
Start Date
July 1 2014
End Date
July 1 2022
Last Update
November 17 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongshan Ophthalmic Center
Guangzhou, Guangdong, China, 510060